Candel Therapeutics (CADL) Net Cash Flow (2020 - 2025)

Candel Therapeutics' Net Cash Flow history spans 4 years, with the latest figure at -$7.6 million for Q4 2023.

  • On a quarterly basis, Net Cash Flow fell 6.25% to -$7.6 million in Q4 2023 year-over-year; TTM through Dec 2023 was -$34.6 million, a 171.9% decrease, with the full-year FY2025 number at $17.2 million, down 74.38% from a year prior.
  • Net Cash Flow hit -$7.6 million in Q4 2023 for Candel Therapeutics, up from -$8.9 million in the prior quarter.
  • Over the last five years, Net Cash Flow for CADL hit a ceiling of $64.1 million in Q3 2021 and a floor of -$10.8 million in Q1 2023.
  • Historically, Net Cash Flow has averaged $1.1 million across 4 years, with a median of -$6.4 million in 2021.
  • Biggest five-year swings in Net Cash Flow: skyrocketed 2964.06% in 2021 and later tumbled 192.37% in 2023.
  • Tracing CADL's Net Cash Flow over 4 years: stood at $16.8 million in 2020, then plummeted by 134.19% to -$5.7 million in 2021, then fell by 24.09% to -$7.1 million in 2022, then fell by 6.25% to -$7.6 million in 2023.
  • Business Quant data shows Net Cash Flow for CADL at -$7.6 million in Q4 2023, -$8.9 million in Q3 2023, and -$7.4 million in Q2 2023.